Literature DB >> 9490406

HIV vaccines. Viral envelope fails to deliver?

D P Bolognesi, T J Matthews.   

Abstract

Mesh：

Substances：

Year:  1998        PMID： 9490406     DOI： 10.1038/35504

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  5 in total

1.  Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization.

Authors:  Bimal K Chakrabarti; Wing-pui Kong; Bei-yue Wu; Zhi-Yong Yang; Jacques Friborg; Xu Ling; Steven R King; David C Montefiori; Gary J Nabel
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

2.  HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.

Authors:  Bimal K Chakrabarti; Marie Pancera; Sanjay Phogat; Sijy O'Dell; Krisha McKee; Javier Guenaga; James Robinson; John Mascola; Richard T Wyatt
Journal:  AIDS Res Hum Retroviruses       Date:  2011-01-19       Impact factor: 2.205

3.  The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection.

Authors:  Abraham Pinter; William J Honnen; Yuxian He; Miroslaw K Gorny; Susan Zolla-Pazner; Samuel C Kayman
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

Review 4.  A New Scientific Paradigm may be Needed to Finally Develop an HIV Vaccine.

Authors:  José Esparza
Journal:  Front Immunol       Date:  2015-03-18       Impact factor: 7.561

5.  Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected individuals.

Authors:  S Beddows; S Lister; R Cheingsong; C Bruck; J Weber
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.